Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

Clinical trial NCT04874194 · TERMINATED

Trial details

NCT number: NCT04874194
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hematopoietic and Lymphoid Cell Neoplasm Recurrent Acute Biphenotypic Leukemia Recurrent Acute Myeloid Leukemia Recurrent Myelodysplastic Syndrome Refractory Acute Biphenotypic Leukemia Refractory Acute Myeloid Leukemia Refractory Myelodysplastic Syndrome

Start date: 2021-12-17
Primary completion: 2024-09-16
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.